CSO Dr Roly Foulkes discusses importance of immune resetting at Biotrinity 2019


Immune Regulation Limited (‘Immune Regulation’ or the ‘Company’) a biopharmaceutical company developing “first in class” immune-resetting therapies for asthma and other inflammatory diseases, announces that Dr. Roly Foulkes, Chief Scientific Officer, took part in a panel discussion titled “What’s New in Autoimmune Disease?” at the BioTrinity 2019 conference in London on 1 May 2019.

Alongside leading industry peers from Cambridge Immunology Network, Eli Lilly, M Ventures and UCL, Dr Foulkes discussed the importance of immune system resetting, potential targets for autoimmune drug development, priority autoimmune diseases for research and what biotechnology companies working in this space need to succeed.

Established in 2007, BioTrinity is Europe’s leading biopartnering and investment conference, It brings life science companies, academics, investors, and major pharmaceutical players together for partnering and to debate key industry themes and issues. Being selected to contribute to this panel is an endorsement of the potential of Immune Regulation’s approach.

Dr Foulkes commented, “Discussing the importance of immune resetting therapies in the treatment of autoimmune diseases with such a high calibre panel was an excellent opportunity to highlight our novel approach. Our technology has the potential to return an out-of-balance immune system to its normal state, putting patients into long-term disease remission, without the significant side effects seen with current chronic therapy.”

Immune Regulation
Richard Nagle, CEO
+44 (0)7809 525267

Instinctif Partners
Melanie Toyne-Sewell / Rozi Morris
+44 (0)20 7457 2020

About Immune Regulation Limited
Immune Regulation is a clinical stage biotech company, pioneering new technologies for resetting the immune system, developing novel, first-in-class therapies for inflammatory and immunological diseases. These therapies reset the immune system from a pro-inflammatory to a regulatory state to induce long-term disease remission in patients with allergic and immune mediated diseases, without the negative effects of chronic current therapies.

Lead drug candidates, IRL201805 (‘1805) and IRL201104 (‘1104) have successfully completed Phase 1/2a and Phase 1 studies, respectively. Both molecules have demonstrated a durable regulation of the immune system for a significant time period after a single dose and both appear to have very clean safety profiles. They appear to modulate key cells of the immune system that control the inflammatory response, with a long duration of action following a single dose (‘1805, up to 12 weeks; ‘1104, up to 14 days) despite their short pharmacokinetic half-lives. Furthermore, despite regulating the immune system they do not appear to suppress host defence, having shown no impact to date on the body’s ability to fight infection. Rather, they are immunomodulators: they appear to reset the immune response with the potential for inducing long-term disease remission.

7 May 2019